GenXys Health Care Systems

About:

SaaS software company specializing in Precision Prescribing Software with embedded Pharmacogenetics interpretation and translation.

Website: https://www.genxys.com/

Twitter/X: MyGenXys

Top Investors: Creative Destruction Lab (CDL), TELUS Ventures, Esplanade Ventures, GreenShield

Description:

GenXys is a leader in precision prescribing software with pharmacogenetics which enables clinicians to make prescribing decisions with confidence and accuracy. The GenXys Platform is used by molecular lab companies to do clinical translation and interpretation of their pharmacogenetic tests and provide this information in a real time clinically usable format at ANY point of care. The GenXys platform is widely used across Canada and the US addressing a top 5 global cause of death, Adverse Drug Reactions. GenXys is fulfilling its vision of every prescription, globally, being made better by its software in a quest to enable precision medicine for everyone.

Total Funding Amount:

4.77M CAD

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Vancouver, British Columbia, Canada

Founded Date:

2014-07-31

Contact Email:

info(AT)genxys.com

Founders:

Karl Pringle, Mark Gelfer, Martin Dawes

Number of Employees:

11-50

Last Funding Date:

2020-03-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai